Peri-Implantitis

PHILADELPHIA, April 23, 2024 /PRNewswire/ -- Every year, roughly 3 million Americans receive implants to replace lost teeth. While this technology has represented a leap of progress in dental care, over time, inflammation and gum disease ― nurtured by microbial biofilms, or plaque ― can affect the soft tissue and bone surrounding the implant and cause these tooth replacements to fail. An innovative new implant now on the horizon may one day address these issues, disrupting biofilms through its inherent antimicrobial and anti-inflammatory properties. The design of this next generation implant is the work of Dr. Geelsu Hwang at Penn Dental Medicine, who has a background in engineering that he brings to his research on biofilms and their role in oral health. "The lack of a good seal between the implant structure and the surrounding gum, compared to a natural tooth, means that the risk of disease around the implant is quite high," Hwang says. The new implant he and his collaborators are developing would interfere with biofilms and combat peri-implant infection in two ways: First, the crown, the artificial tooth atop the implant structure, will be suffused with nanoparticles made of a chemical compound that naturally wards off bacteria. Hwang and his team have been experimenting with the compound barium titanate (BTO). Second, the base of the crown will contain LEDs that deliver a regular dose of phototherapy to the surrounding gum tissue, giving off light at a wavelength that has antibacterial and anti-inflammatory properties. The LEDs will be powered by the piezoelectric material in the crown (like the BTO) that converts the motion of chewing or toothbrushing to electrical energy. Hwang notes that this platform could one day be integrated not only into dental implants, but into other applications, such as joint replacements, as well. In 2023, the National Institutes of Health awarded Hwang a five-year grant to further advance the implant development. The NIH funding will support tests of the new implant technology, using laboratory cultures of human gum tissue and, ultimately, test implants in mini pigs as preparation for human clinical trials. In related research, he is also studying a new piezoelectric dental composite material for fillings. The material would generate an enhanced electrical charge at the interface from the mechanical pressure of chewing, and this on its own would inhibit bacterial colonization of the composite surface. Contact: Beth Adams [email protected] SOURCE Penn Dental Medicine

2024年2月，易岭生物自主研发生产的口腔软硬组织再生类产品“口腔用骨填充材料（诚谷快®）”获NMPA三类医疗器械注册证。这也是易岭生物的第一个医疗器械注册证。易岭生物成立于2017年，专注于生物智能再生材料的创新研发与产业化。易岭生物创始人、CEO许力心博士表示，此次获批是口腔软硬组织缺损智能修复领域的一项重大突破，产品上市后将为消费者提供更好的治疗选择。“获批产品的主要创新点在于改变了传统的植骨方式，让植骨更便捷有效，能够克服第一代生物惰性材料和第二代生物活性材料的一些无法解决的问题，即快速植骨后可以快速诱导骨生成，同时植骨材料及时降解，形成真正的自体骨组织。产品通过精密工艺控制，精细地保留了动物组织的天然胶原三维多孔结构，抗压性能强，足以对抗黏膜压力，为骨组织重建提供稳定空间支持，促进骨再生；同时确保活性因子在材料中具有优良的渗透性和稳定性，实现其在骨组织再生与修复中的最大化生物活性。”许力心博士说道。多条口腔产品管线进入注册阶段，未来将拓展至外科、骨科等领域随着居民健康意识的提升、老龄化进程加速，以及种植牙集采降价的驱动，种植牙市场进入快速增长期，与种植牙紧密相关的口腔骨植入材料市场也有望分享种植牙高速增长红利。深耕口腔骨植入材料市场的易岭生物也迎来了发展期。截至2023年底，30项发明专利和26项使用新型专利，为易岭生物高筑技术壁垒。易岭生物基于口腔软硬组织再生生物支架材料制备的核心技术和工艺流程，已建立丰富的技术储备和产品管线，诸多产品在陆续进入注册阶段，2024年有望拿到2-3张国内NMPA医疗器械注册证。关于口腔修复材料，易岭生物以口腔种植软硬组织修复材料为主的诚谷快®口腔用胶原蛋白填充材料和诚谷快®口腔可吸收修复膜，在国际范围内亦有竞争优势。此次获批的“诚谷快®口腔用胶原蛋白填充材料”由牛松骨经脱细胞、脱脂、脱钙处理后形成的骨基质，主要成分是I型胶原蛋白，更有利于人体吸收，可针对性解决现有口腔组织再生材料存在的降解速度慢、成骨转化率不高、炎症与免疫原性风险等痛点。这一产品的应用场景也非常丰富，可用于拔牙窝位点保存、骨开裂填充、牙周骨缺重建、种植体周围炎骨重建等。相较于传统产品，产品操作简单，更好塑性，大幅缩短临床操作时间的同时，降低了临床医生资历门槛。易岭生物的诚谷快®口腔可吸收修复膜直接由动物源生物膜材料经专利脱细胞技术制备，不适用任何交联剂，保证产品的高度生物相容性；且具有粗糙多孔面及平滑致密面的双面结构，引导骨再生的同时阻止软组织长入新生骨组织中，屏障作用可长达12周。诚谷快®口腔可吸收修复膜在上颌窦提升保护窦底黏膜、牙槽骨重建牙周再生术、种植体周围炎、恶性肿瘤切除等临床应用上均取得了良好效果。值得一提的是，易岭生物致力于成为一家拥有再生医学材料与创新植入器械全方位研发和生产能力的平台型企业，正积极把在口腔领域积累的组织工程支架材料研发、脱细胞、生长因子装载等技术，扩展到外科、神经外科、骨科和皮肤科等领域。北大和中科院博士联合创业，已完成三轮融资在创办易岭生物前，许力心博士就职于北京大学口腔医院，曾任北京大学口腔医院第二门诊部种植学术委员会秘书长、第三门诊部种植中心主任，综合一科主任，在国内开展了近百场种植修复培训课程，口腔类受益医生达数千人。同时，许力心博士也热爱科研事业，主持了多项与组织再生相关科研项目，拥有47项发明及实用新型专利47项，6项外观专利。在临床中发现患者需求，进而在科研中寻找答案。在发现市场主流的口腔修复材料与患者需求的不匹配、与临床医生操作便捷性之间的矛盾愈发明显后，“我想找到一种对患者友好且方便医生操作的生物智能再生材料”，研究组织再生多年的许力心博士躬身入局，走上了创业道路。“确定创业后，我第一想法是寻找在再生材料这块最有经验的伙伴。”具有权威行业地位的中科院再生医学研究中心成为她的第一选择。随后，中科院遗传所博士、中国科学院再生医学中心研究员陈冰博士作为联合创始人、CTO加入易岭生物。陈冰博士师从著名再生医学专家戴建武教授，长期从事干细胞与再生医学领域组织损伤修复研究，主导了国家自然基金、科技部863课题及国家重点研发计划课题，不仅在生物材料及生长因子研究及开发领域有独到见解，还有着丰富的科研项目组织及管理经验，且非常熟悉三类医疗器械产品注册标准、医疗器械检验报批流程。商业化能力是每个企业家都无法回避的话题。临床出身的许力心博士相信“勤能补拙”，在积极吸纳优秀商业化人才的同时，也进行高效学习，不断完善对企业运营管理的认知。至今，易岭生物已建立了一支来自国内一流科研机构和医疗机构的精英团队，拥有丰富的技术研发、生产管理、注册报证、临床推广、渠道搭建以及商业落地能力。基于创始团队在临床与产业端的多年积累，易岭生物还与一线专家教授、国内知名医疗机构、口腔器械龙头企业组成了紧密的产学研一体化创新机制。这对易岭生物的前期产品研发、后期市场推广都起到了极大的助力。易岭生物基于完善的研发、生产、销售和服务一体化管理体系，业务已覆盖北京、天津、深圳等全国近20个省市，意向订单金额超过千万元。许力心博士分享道，易岭生物计划在五年内服务一万家口腔门诊。自成立以来，易岭生物已完成三轮融资。2024年，易岭生物为加速核心产品的研发升级，推进产品在国内外市场的快速商业化落地，计划开展新一轮融资。动脉网第八届未来医疗100强大会现已升级为，将于2024年5月7日-10日在北京·北人亦创国际会展中心盛大举行。本届展会为15000+人次、10000平规模，围绕新产品、新技术、新服务、新生态、新合作构建体系，为医疗健康产业的创新力展示搭建最佳舞台。这里是，公认的医疗产业创新洞察的生成地，年度趋势分享与学习交流的口碑盛会；优秀的医疗创新企业和创新产品都在这，是企业展示创新和面谈合作的最佳场景；这里有，最具前瞻力的思享盛会：500+大咖嘉宾莅临分享，3天主论坛、40余场主题论坛，只做干货议题！最具创新力的生态链接：5大展区，200+首发首创新品、3000+企业、500+投资团，全球买手云集！最具影响力的榜单发布：上市公司创新力榜+未来医疗100强榜+创新力产品榜，700+上榜企业现场交流！目前已有超过600家企业和产品确认参加展会，展览面积预订超过70%，全球买手团已合作了印度尼西亚、新加坡、比利时、爱尔兰、西班牙、德国、澳大利亚、英国、加拿大等国家。余下的合作席位已不多，欢迎企业、品牌方、买手团或相关组织洽谈参会。在这个充满不确定性的时代，寻求高价值资源和高效率链接，将是您的首选。即刻报名，限时福利！声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

SALT LAKE CITY--(BUSINESS WIRE)-- Spectrum Solutions®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™. As advances in science continue to focus on the mouth-body connection and its direct link to systemic disease, SimplyPERIO™ fills a testing void by delivering more intelligent health measures with real clinical relevance using 16 oral targets from a single patient sample. Gum disease, also called periodontal disease, is one of the most undiagnosed and untreated diseases, but has some of the highest negative impacts on many bodily systems and functions. In addition, gum disease decreases a person’s ability to fight infection and inflammation. SimplyPERIO™ uses a proprietary molecular technology to test for and measure periodontal bacteria, caries, fungal and viral targets all for one affordable cost. Understanding treatment success is often influenced by host immunity and host response, this unique, highly sensitive and highly specific saliva test offers Providers the real opportunity to elevate patient care with the most complete oral health picture. “We are using science to make saliva diagnostics simple for both Patients and Providers. SimplyPERIO™ testing is not only pain-free it takes less than 30 seconds for a patient to collect their own sample,” said Dr. David Vigerust, PhD, Chief Science Officer at Spectrum Solutions. “In addition, our CAP accredited laboratory delivers Providers the independent, 3rd party results necessary for intelligent, data-supported patient conversations about stopping and even reversing their disease and systemic risks.” In the U.S., numbers illustrate that 80% of individuals over 35 have a form of gum disease. Gingivitis, periodontitis and peri-implantitis are all forms of gum disease. These numbers demonstrate that for the vast majority, there may be dangerous and damaging periodontal disease pathogens hiding that can't be identified with a perio-probe or visual exam during regular semi-annual cleanings. Gone unchecked, these harmful oral bacteria and toxins are allowed to sit and accumulate inside the mouth. From inside the mouth these microorganisms move freely to and through the bloodstream with far reaching and catastrophic effects on the heart, arteries, central nervous system and more. The SimplyPERIO™ patented blue buffer solution located inside the collection device’s cap stabilizes saliva samples at room temperature eliminating any special post-collection storage or shipping requirements. Easily deposit one at a time, supporting at-home patient testing for follow-up and treatment monitoring, or gather an entire day’s worth of in-office collections into the USPS postage-paid return box for mailing samples back to the lab for processing. ABOUT SPECTRUM SOLUTIONS® Headquartered in Salt Lake City, Utah, Spectrum Solutions is dedicated to empowering complete wellness and bridging the gap between science and innovative healthcare solutions. Our stand-alone and fully integrated test-to-treat solutions support molecular diagnostics and DTC testing applications, advancing product development and accelerating go-to-market applications. Our single-source, end-to-end capabilities include a CAP accredited molecular diagnostic laboratory, onsite compounding pharmacy, product development, manufacturing and fulfillment. SimplyTest® and Spectrum Solutions® are registered trademarks of Spectrum Solution, LLC. For more information, please visit spectrumsolution.com or simplytest.com.